UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

Alterola Biotech, Inc.

(Exact name of Registrant as specified in its charter)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days

[X] Yes [ ] Yes [X] No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). [X] Yes [ ] No [X]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

[X] ] Yes [ ] [X] No

State the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 114,980,000 common807,047,948 shares as of May 5, 2016August 11, 2023.

PART I - FINANCIAL INFORMATION

Item 1.     Financial Statements

Our consolidated financial statements included in this Form 10-Q are as follows:

These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and the SECSecurities Exchange Commission (“SEC”) instructions to Form 10-Q.  In the opinion of management, all adjustments considered necessary for a fair presentation have been included.  Operating results for the interim period ended March 31, 2016June 30, 2023 are not necessarily indicative of the results that can be expected for the full year.

ALTEROLA BIOTECH, INC.

CONDENSEDUNAUDITED CONSOLIDATED BALANCE SHEETS (unaudited)

AS OF JUNE 30, 2023 AND MARCH 31, 2023

See accompanying notes to financial statements.

ALTEROLA BIOTECH, INC.

CONDENSED STATEMENTSUNAUDITED CONSOLIDATED STATEMENT OF OPERATIONS (unaudited)

FOR THE THREE MONTHS ENDED JUNE 30, 2023 AND 2022

See accompanying notes to financial statements.

Table of Contents

ALTEROLA BIOTECH, INC.

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ DEFICIT

FOR THE PERIOD FROM JANUARY 7, 2021 (INCEPTION) TO JUNE 30, 2023

ALTEROLA BIOTECH, INC.

CONDENSED STATEMENTS OF CASH FLOWS (unaudited)

See accompanying notes to financial statements.

ALTEROLA BIOTECH, INC.

UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS

FOR THE THREE MONTHS ENDED JUNE 30, 2023 AND 2022

NOTES TO THE CONDENSEDUNAUDITED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

MARCH 31, 2016JUNE 30, 2023

NOTE 1 – NATURE OF BUSINESS

Alterola Biotech, Inc. (“Alterola” and

After formation, the “Company”) is a development stage company and was incorporated in Nevada on July 21, 2008. The Company was formed forin the purposebusiness of acquiring exploration and development stage mineral properties.

On October 1, 2008, the Company incorporated JRE Exploration Ltd, (“JRE”) a wholly owned subsidiary in Canada for the purpose of holding its Canadian mineral claims.

exploration. On May 3, 2010, the Company sold its mineral exploration business and entered into an Intellectual Property Assignment Agreement (“IP Agreement”) with Soren Nielsen pursuant to which Mr. Nielsen transferred his right, title and interest in all intellectual property relating to certain chewing gum compositions having appetite suppressant activity (the “IP”) to the Company for the issuance of 55,000,000 shares of the Company’s common stock.

Following the acquisition of the IP the Company changed its focusbusiness direction to pursue the development of chewing gums for the delivery of Nutraceutical/functional ingredients for applications such as appetite suppressant, cholesterol suppressant, vitamin delivery, antioxidant delivery and motion sickness suppressant.

On January 19, 2021, the Company entered into an Stock Purchase Agreement (the “Agreement”) with ABTI Pharma Limited, a company registered in England and Wales (“ABTI Pharma”), pursuant to which the Company agreed to acquire all of the outstanding shares of capital stock of ABTI Pharma from its shareholders in exchange for 600,000,000 shares of the Company pro rata to the ABTI Pharma shareholders. The shares were issued on January 29, 2021 in anticipation of the closing and the parties to the transaction agreed in a March 24, 2021 amendment to close upon the ABTI Pharma Limited Shares being transferred to the Company, which was to occur upon the filing by the Company of its outstanding December 31, 2020 quarterly report on Form 10-Q, which was filed on May 28, 2021 with the Securities and Exchange Commission. The transaction closed on May 28, 2021.

The transaction is being accounted for as a reverse acquisition and recapitalization. ABTI Pharma is the acquirer for accounting purposes and the Company is the issuer. The historical financial statements presented are the financial statements of ABTI. The Agreement was treated as a recapitalization and not as a business combination; at the date of the acquisition, the net liabilities of the legal acquirer, Alterola, were $389,721.

The business plan of the company will no longer be focused on a chewing gum delivery system but it will re-focus its activities to the development of cannabinoid, cannabinoid-like, and non-cannabinoid pharmaceutical active pharmaceutical ingredients (APIs), pharmaceutical medicines made from cannabinoid, cannabinoid-like, and non-cannabinoid APIs and European novel food approval of cannabinoid-based, cannabinoid-like and non-cannabinoid ingredients and products .In addition, the company plans to develop such bulk ingredients for supply into the cosmetic sector.

As of July 05, 2023 we acquired intellectual property and accordingly sold JRE to the former president. (See Note 3). In keeping with the change of business focus, on July 9, 2010, the Company changed its name to Alterola Biotech Inc.

Effective July 9, 2010, the Board of Directors authorized a 10 for 1 forward stock split on the issued common shares. The authorized number of common shares was increased from 90,000,000 to 140,000,000 common shares with a par value of $0.001. The number of authorized Preferred shares remained unchanged at 10,000,000 with a par value of $0.001. All referencesAlinova Biosciences Ltd. We acquired Alinova’s joint interest in the accompanying financial statements to the numberpatent family PTX P0001. We paid total upfront costs of common£35,000 Sterling in cash and 5,000,000 shares have been restated to reflect the forward stock split.of ABTI stock.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Accounting Basis

The Company uses the accrual basis of accounting and accounting principles generally accepted in the United States of America (“GAAP” accounting).  The Company has adopted a September 30 fiscal year end.

Basis of Presentation

The accompanying unaudited interimconsolidated financial statements of Alterola Biotech Inc. have beenwere prepared in accordance with accounting principles generally accepted in the United StatesState of America (GAAP accounting) and include the rulesaccounts of the SecuritiesAlterola and Exchange Commission (“SEC”),its wholly owned subsidiaries ABTI Pharma, Phytotherapeutix Ltd, Ferven Ltd.. All material intercompany transactions and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s registration statement filed with the SEC on Form 10-K. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for the financial statements to be not misleadingbalances have been reflected herein.eliminated.

 The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year. NotesCompany had a September 30 fiscal year end. Subsequent to the financial statements which would substantially duplicateAgreement with ABTI Pharma, the disclosure contained in the audited financial statements for the most recent fiscalCompany has changed its year 2015 as reported in Form 10-K, have been omitted.end from September 30 to March 31.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principlesGAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents

For purposes of the statement of cash flows, the Company considers highly liquid financial instruments purchased with a maturity of three months or less to be cash equivalents.

ALTEROLA BIOTECH, INC.

NOTES TO THE CONDENSED FINANCIALUNAUDITED CONSOLIDATEDEDFINANCIAL STATEMENTS (unaudited)

MARCH 31, 2016JUNE 30, 2023

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Intellectual Property

The Company does not amortize intangible assets with indefinite useful lives, rather such assets are required to be tested for impairment at least annually or sooner whenever events or changes in circumstances indicate that the assets may be impaired. The Company amortizes its intangible assets with definite lives over their estimated useful lives and reviews these assets for impairment. The Company will amortize its acquired intangible assets with definite lives over the estimated economic life of the completed product. During the year ending September 30, 2011, the value of the intellectual property was determined to be $0 and impairment expense of $21,500 was recorded.

Website Development Costs

Costs incurred in developing and maintaining a website are charged to expense when incurred for the planning, content population, and administration or maintenance of the website. All development costs for the application, infrastructure, and graphics development are capitalized and subsequently reported at the lower of unamortized cost or net realizable value. Capitalized costs will be amortized using straight-line basis over two years, the estimated economic life of the completed website. For the six months ended March 31, 2016, the depreciation expense for the company’s website was $1,550, as compared to $0 for the same period ended 2015.

Fair Value of Financial Instruments

Alterola’s financial instruments consist of cash and cash equivalents, accrued expenses, accrued interest and notes payable. The carrying amount of these financial instruments approximates fair value (“FV”) due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements.

Fair valueFV is defined as the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. The fair valueFV should be calculated based on assumptions that market participants would use in pricing the asset or liability, not on assumptions specific to the entity. In addition, the fair valueFV of liabilities should include consideration of non-performance risk including our own credit risk.

In addition to defining fair value,FV, the disclosure requirements around fair valueFV establish a fair valueFV hierarchy for valuation inputs which is expanded. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair valueFV are observable in the market. Each fair valueFV measurement is reported in one of the three levels which is determined by the lowest level input that is significant to the fair valueFV measurement in its entirety. These levels are:

Level 1 – inputs are based upon unadjusted quoted prices for identical instruments traded in active markets.

Level 2 – inputs are based upon significant observable inputs other than quoted prices included in Level 1, such as quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

ALTEROLA BIOTECH, INC.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS (unaudited)

MARCH 31, 2016

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Fair Value of Financial Instruments (continued)

Level 3 – inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The fair valuesFV are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques.

The carrying value of the Company’s financial assets and liabilities which consist of cash, accounts payable and accrued liabilities, and notes payable are valued using level 1 inputs. The Company believes that the recorded values approximate their fair valueFV due to the short maturity of such instruments. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest, exchange or credit risks arising from these financial instruments.

Income Taxes

Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.

ALTEROLA BIOTECH, INC.

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2023

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Foreign Currency Translation

The financial statements are presented in US Dollars. Transactions with foreign subsidiaries where US dollars are not the functional currency will be recorded in accordance with Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 830 Foreign Currency Transaction. According to Topic 830, all assets and liabilities are translated at the exchange rate on the balance sheet date, stockholders’ equity is translated at historical rates and statement of operations items are translated at the weighted average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income (loss) in accordance with ASC Topic 220, Comprehensive Income . Gains and losses resulting from the translations of foreign currency transactions and balances are reflected in the statement of operations and comprehensive income (loss )

Revenue Recognition

TheOn January 1, 2018, the Company will recognize revenue when productsadopted ASC Topic 606, Revenue from Contracts with Customers ("ASC 606"), using the modified retrospective method applied to those contracts which were not completed as of January 1, 2018. Results for reporting periods beginning after January 1, 2018 are fully delivered or services have been providedpresented under ASC 606, while prior period amounts are not adjusted and collection is reasonably assured.continue to be reported in accordance with our historic accounting under ASC 605. As of and for the year ended June 30, 2022, the financial statements were not materially impacted as a result of the application of Topic 606 compared to Topic 605.

Loss Per Common Share

Basic loss per share is calculated using the weighted-average number of common shares outstanding during each reporting period. Diluted loss per share includes potentially dilutive securities such as outstanding options and warrants, using various methods such as the treasury stock or modified treasury stock method in the determination of dilutive shares outstanding during each reporting period. The Company does not have any potentially dilutive instruments.

Stock-Based Compensation

Stock-based compensation is accounted for at fair valueFV in accordance with ASC Topic 718. To date, the Company has not adopted a stock option plan and has not granted any stock options.options

DuringResearch and development

We engage in a variety of research and development activities to develop our technologies and work toward development of a saleable product. When it is determined that the year ended Septemberresearch and development products we are creating have reached a point where saleable products are possible, these amounts are capitalized. As of June 30, 2013,2023 and March 31 ,2023 there are no capitalized research and development costs.

The research and development costs incurred by the company relate to the following:

ALTEROLA BIOTECH, INC.

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2023

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Other Intangible Assets

We have recorded the assets acquired as part of the C2 Wellness acquisition as indefinite lived Intangible assets. Indefinite life intangible assets recorded are not amortized and, as a result, are assessed for impairment at least annually, using either a qualitative or quantitative process. We performed this annual assessment as of March 31, 2023, noting no factors indicating possible impairment of intangible assets recognized. 

Risks and Uncertainties

On January 30, 2020, the World Health Organization declared the coronavirus outbreak a “Public Health Emergency of International Concern” and on March 10, 2020, declared it to be a pandemic.  Actions taken around the world to help mitigate the spread of the coronavirus include restrictions on travel, and quarantines in certain areas, and forced closures for certain types of public places and business.  The Coronavirus and actions taken to mitigate it have had and are expected to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which the Company issued 37,000,000 shares of common stockplans to its director.operate.”

Recent Accounting Pronouncements

Alterola does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

ALTEROLA BIOTECH, INC.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS (unaudited)

MARCH 31, 2016

NOTE 3 – ACCRUED EXPENSES

Accrued expenses consisted of the following at June 30, 2023 and March 31, 2016 and September 30, 2015:2023

During the period ended December 31, 2015, the Company negotiated a settlement of certain legal expenses, in which $10,173 of accrued invoices was forgiven.

NOTE 4 – NOTES PAYABLE

Notes payable consisted of the following at March 31, 2016 and September 30, 2015:

NOTE 5 – CAPITAL STOCK

The Company has 140,000,0002,000,000,000 shares of $0.001$0.001 par value common stock authorized and 10,000,000 shares of $0.001$0.001 par value preferred stock authorized.

On August 6, 2008,During September 2021, the Company issued 55,000,000 common shares to the Company’s president at $0.001 per sharereceived an investment for total proceeds of $55,000.

On September 22, 2008, the incumbent president resigned as both an officer and director and£100,000 Sterling (or $137,627) in exchange for a new president and director was appointed. At the request of the departing president, the Company’s board of directors rescinded his share subscription for 55,000,000 common shares and repaid the subscription proceeds of $55,000.280,000 shares.

On September 22, 2008, the Company issued 55,000,000 common shares to the Company’s new president at $0.00095 per share for total proceeds of $52,246.

On September 22, 2008, the Company issued 39,600,000 common shares at approximately $0.00149 per share for total proceeds of $55,740 pursuant to a private placement. On September 30, 2008, the Company issued 2,400,000 common shares at approximately $0.00149 per share for total proceeds of $3,467 pursuant to a private placement. The Company paid a commission of $5,700 for net proceeds of $53,507 for these private placements.

On October 29, 2008,2021, the Company issued 2,400,000 common7,500,000 shares of stock in exchange for services provided by EMC2 Capital LLC. The shares were issued at approximately $0.00119 per share for total proceedsfair value of $2,865the date of exchange, or $2,399,250.

As pursuant to a private placement.

On January 5, 2010, pursuant to a share subscriptionthe asset purchase agreement dated November 9, 2021, the Company acquired certain intellectual property rights of C2 Wellness Corp. In exchanges for the assets acquired, the Company issued 33,330,000 Common Shares24,000,000 shares of common stock valued at $0.0015$0.50 per share. The intellectual property rights acquired are recorded as intangible assets as of December 31, 2021 for aggregate proceeds of $50,000.$12,000,000.

ALTEROLA BIOTECH, INC.

NOTES TO THE CONDENSEDUNAUDITED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

MARCH 31, 2016JUNE 30, 2023

NOTE 54 – CAPITAL STOCK (CONTINUED)

On May 3, 2010, pursuant to the sale of JRE Exploration Ltd. (Note 3) the Company received 55,000,000 of its Common stock from the former Company president with a fair value of $52,246 for cancellation, as consideration for the sale of JRE, our wholly owned subsidiary.

On November 17, 2010, the President entered into a stock cancellation agreement the Company whereby 40,000,000 common shares were returned to treasury and cancelled. In consideration the Company will issue to the President options to acquire common stock pursuant to the stock option plan which will be adopted by the Company at some time in the future.

On December 21, 2010,2021, the company issued 520,000 shares of stock in exchange for $130,000 of cash consideration.

On February 8, 2022, the company issued 333,333 shares to an investor for an investment of $50,000 (at a price of $0.15 per share).

On or about March 3, 2022, the Company issued 250,000 shares at $0.20 for aggregate proceeds of $50,000.

In February 2011, the former President returned 15,000,00016,000,000 shares of common stock for voluntary cancellation.services under a consulting agreement.

On July 16, 2013,April 5, 2022, the company issued 384,615 shares to an investor for an investment of $50,000 (at a price of $0.13 per share).

On April 29, 2022, the Company issued 37,000,0001,500,000 shares for services under a consultancy agreement at $0.214 per share, or $321,000.

On May 2, 2022, the Company issued 280,000 shares to an investor relating to a subscription agreement for an investment of £100,000 Sterling (or $136,721) at $0.50 per share, or $140,000.

On May 4, 2022, we issued 2,250,000 shares of our common stock to our director, Mr. Michael Hunter Land, pursuant to his employment agreement dated October 18, 2021 and board decision to award him shares for his performance.

On August 1, 2022, the Company signed loan agreements with note holders for the sum of $75,000. A total of 2,250,000 shares were issued to the note holders in connection with loan agreements. See Note 5. These loans were repaid in full by December 23, 2022. 

On June 6, 2023, the Company reclaimed 44,064,000 shares into Treasury

On June 13, 2023, we issued 13,500,000 shares of common stock to its directorEMC2 Capital LLC following the cashless exercise of their 15,000,000 Warrants issued in August 2021.

On June 13, 2023, we issued 476,000 shares of common stock to Alison Rose Burgess as settlement of a £125,000 Sterling loan under the terms and conditions of the loan dated 21 September 2021.

On June 13, 2023, we issued 5,000,000 shares of common stock to Alinova Biosciences Ltd as part payment of consideration for the acquisition of intellectual property.

June 13, 2023, we issued 5,999,900 shares of common stock to Long Eight Limited as part payment of consideration for services received by Green Ocean Administration Limited.

June 13, 2023, we issued 10,088,100 shares of common stock to Warren Law Group to be held in escrow as potential part payment for services received from Bridgeway Capital Partners LLC, Bridgeway Capital Partners II LLC and Entoro Securities LLC.

On June 14, 2023, we issued 9,000,000 shares of common stock to our Directors as payment for their services as Directors.

These securities were issued pursuant to Section 4(a)(2) of the Securities Act and/or Rule 506 promulgated thereunder. The holders represented their intention to acquire the securities for investment only and not with a deemed value of $37,000.view towards distribution. The investors were given adequate information about us to make an informed investment decision. We did not engage in any general solicitation or advertising. We directed our transfer agent to issue the stock certificates with the appropriate restrictive legend affixed to the restricted stock.

The Company has 114,980,000807,047,948 and 114,980,000807,047,948 shares of common stock issued and outstanding as of June 30, 2023 and March 31, 2016 and September 30, 20152023, respectively. There are no shares of preferred stock issued and outstanding as of June 30, 2023 and March 31, 20162023.

On June 30, 2023, the Company issued 476,000 shares of common stock in settlement of a convertible promissory note payable in the amount of $157,815. The conversion of the note payable into shares resulted in a loss on conversion of $138,639 which has been recorded on statement of operations for the period ended June 30, 2023.

NOTE 5 – NOTES PAYABLE

On August 1, 2022, the Company issued a note payable for 90 days bearing zero interest for the term of the note, for cash received by the Company on June 29, 2022 and September 30, 2015.July 18, 2022 totaling $75,000. As part of the note the Company committed delivery of 2,250,000 shares to the note holders. The loans totaling $75,000 were repaid in full by December 23, 2022.

NOTE 6 – RELATED PARTY TRANSACTIONS

Alterola neither owns nor leases any real or personal property. An officer has providedAlterola leases office space without charge. There is no obligation for the officer to continue this arrangement.from a director at an independently determined commercial rate. Such costs are immaterial to the financial statements and accordingly are not reflected herein. The officers and directors are involved in other business activities and most likely will become involved in other business activities in the future.

During the period ended June 30, 2023, a number of shareholders made advances to the company to fund operating expenses in the amount of $1,372,947. These advances are non – interest bearing and have no specified terms of repayment.

NOTE 7 – LIQUIDITY & GOING CONCERN

Alterola has negative working capital of $2,102,860, has incurred losses since inception of $10,295,080, and has not yet received revenues from sales of products or services. These factors create substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern.

The ability of Alterola to continue as a going concern is dependent on the Company generating cash from the sale of its common stock and/or obtaining debt financing and attaining future profitable operations. Management’s plans include selling its equity securities and obtaining debt financing to fund its capital requirement and ongoing operations; however, there can be no assurance the Company will be successful in these efforts.

NOTE 8 – SUBSEQUENT EVENTS

In accordance with ASC Topic 855-10, the Companyhas analyzed its operations subsequent to March 31, 2016June 30, 2023 to the date these financial statements were issued, and has determined that it does not have any material subsequent events to disclose in these financial statements.

Item 2.     Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.   These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions.  We intend such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of complying with those safe-harbor provisions.  Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain.  Factors which could have a material adverse affect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.  We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.  Further information concerning our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC.

Company Overview

Recent Developments

On May 3, 2010,August 26, 2022, we acquired intellectual property relatingentered into a letter of intent (the “LOI”) dated August 25, 2022 with Bright Green Corporation (“Bright Green”), a Delaware corporation, with a binding provision for Bright Green to certain chewing gum compositions having appetite suppressant activityacquire a 25% interest (the “IP”“Share Purchase”) in our company from existing shareholders in exchange for $4,000,000 (the “Purchase Price”). FollowingThe LOI also has a non-binding option for Bright Green to acquire all of our outstanding capital stock.

The Share Purchase was subject to a Share Purchase Agreement which was executed on October 03, 2022.

The Purchase Price was divided equally among the following shareholder companies for their shares, controlled by affiliates of our company namely: Phyotherapeutix Holdings Ltd (Colin Stott), Equipped4 Holdings Limited (Dominic Schiller) and TPR Global Limited (Timothy Rogers).

These shareholder affiliates, through their respective companies, have committed to enter into loan agreements with our company to provide up to $4,000,000 USD of working capital, subject to the terms and conditions of the signed SPA dated October 03, 2022 being fulfilled.

At present, the Company remains in discussions with Bright Green Corporation with regard to a potential acquisition of Alterola (as per the IP, we commenced pursuing the development of chewing gums for the delivery of nutraceutical/functional ingredients for applications such as appetite suppressant, cholesterol suppressant, vitamin delivery, antioxidant deliverypreviously signed LOI dated August 25, 2022 and motion sickness suppressant.SPA dated October, 03 2022)..

Our plan is to use our IP and develop and market nutraceutical/functional chewing gum and in the future medicinal chewing gum. We are ardently researching new ways to use chewing gum as a delivery system, expanding on the kinds of applications chewing gum has been used for in the past. We initially expected to reveal functional chewing gum for new applications by the end of 2014, but we were not able to do so. We will first need to raise additional capital to develop our chewing gum for the delivery of medicines.

Our mission is to improve the health and quality of life for millions of people all over the world who are unable to or have difficulty with swallowing tablets. As much as 40% of the adult population and an even greater percentage of the adolescent population have difficulties swallowing pills, and we believe our solutions will greatly benefit them.

Presently, we are focused on nutrition and health chewing gum with natural based ingredients. The products below are currently under development and we are working to file patents to protect the ingredients in these products.

• Appetite suppressor
• Cholesterol suppressor
• Antioxidant gum
• Motion sickness suppressor
• Vitamin gum

In order to implement our business plan, however, we will need to raise funds. We were able to secure small loans to pay the legal and accounting fees needed to keep our reporting filings current with the Securities and Exchange Commission. We will need more funds to meet our timetable of introducing Nutraceutical/functional chewing gum. We expect that we will need capital of $500,000 to develop our product.

Our Business

Our goal is to provide better medicines for patients around the world. We believe in harnessing the therapeutic potential of cannabinoids and cannabinoid- like compounds, which can be developed into valuable treatments to seriously ill patients. Rather than just focusing on one method of identifying, researching and developing such medicines, we are interested in developing new medicines from all sources including botanical, traditional chemical synthesis and biosynthetic methodologies.

On May 28, 2021, we acquired ABTI Pharma Limited, a company registered in England and Wales (“ABTI Pharma”), with the purchase of all of its capital stock in exchange for 600,000,000 shares of our common stock pro rata to the ABTI Pharma shareholders.

As a result of the acquisition, we are a pharmaceutical company working with cannabinoid and cannabinoid like molecules. We have three areas of focus:

Phytotherapeutix Ltd, a subsidiary of ABTI Pharma Ltd, has generated a number of molecules with patents pending, some of which have demonstrable pharmacological activity, similar to that of CBD. This means that some of these molecules are anticipated to have a similar market potential to CBD across a range of therapeutic areas.

Ferven Ltd, another subsidiary of ABTI Pharma Ltd, is looking to produce cannabinoids by fermentation. The exclusively licensed organism has the potential to be genetically modified to produce multiple cannabinoids at an anticipated very low cost of goods. It is anticipated that the selected genetically modified organisms will grow very quickly, which in turn, reduces the cost of production.

Nano4M Ltd is a company which has exclusively licensed its nano-formulation patents and know-how to ABTI Pharma Ltd.

As a result of the acquisition of assets and intellectual property from C2 Wellness Corp. on December 2, 2021, Alterola now has the following assets and intellectual property:

• Novel cannabinoid molecules and their associated intellectual property;
• Novel cannabinoid pro-drugs, and their associated intellectual property;
• Novel proprietary cannabinoid formulations, designed to target lymphatic delivery, and their associated intellectual property;
• Novel proprietary nano-encapsulated cannabinoid formulations, in self-dissolving polymers, and their associated intellectual property; and
• Cannabinoids and cannabinoid pro-drug formulations for topical ocular delivery, and their associated intellectual property.

Additionally, we may consider entering into Joint Venture Partnerships, or acquire companies with complimentary portfolios or enter into Licensing Agreements to enhance the product portfolio. These are strategies the Company may implement and any such opportunities will be assessed on a case by case basis and on their merit at the time.

At present, the Company remainsin discussions with Bright Green Corporation with regard to a potential acquisition of Alterola (as per the previously signed LOI dated August 25, 2022 and SPA dated October, 03 2022)..

Alterola and ABTI Pharma Ltd management have extensive experience, know-how and connections in the cannabinoid medicines sector, and are looking to utilize this knowledge and experience for the development of such medicines from existing cannabinoids and cannabinoid-like molecules.

Our address is 47 Hamilton Square Birkenhead Merseyside CH41 5AR United Kingdom. Our telephone number is +44 151 601 9477. Our website is www.alterolabio.com. The company has a fully operational US$ and a £ sterling bank account in the United Kingdom with the HSBC Group.

We do not incorporate the information on or accessible through our websites into this Quarterly Report, and you should not consider any information on, or that can be accessed through, our websites a part of this Quarterly Report.

Results of Operations for the Three and SixNine Months Ended March 31, 2016June 30, 2023 and 20152022

We have generated no revenues since inception and we do not anticipate earning revenuesrevenue until such time that we are able to market and sell our products.ingredients and / or products / medicines.

We incurred operating expenses of $6,009$580,670 for the three months ended March 31, 2016,June 30, 2023, as compared with operating expenses of $2,611$812,689 for the three monthssame period ended March 31, 2015. 2022.

Our operating expenses for the three months ended March 31, 2016 consistedJune 30, 2023 were mainly the result of $2,191 in legal fees, $2,043 in general and administrative expenses, $1,000$48,938 in accounting and audit fees, $35,939 in salaries and $775wages,$317,741 in depreciation. Ourconsulting fees and $171,000 in directors fees. By contrast, our operating expenses for the three months ended March 31, 2015 consistedJune 30, 2022 were mainly the result of $2,111$97,428 in legal feessalaries and $500wage, $34,917 in accounting and audit fees.

We incurred operating expenses of $10,863 for the six months ended March 31, 2016, compared with operating expenses of $7,470 for the six months ended March 31, 2015. Our operating expenses for the six months ended March 31, 2016 consisted of $5,995 in legal fees, $2,318$32,658 in general and administrative expenses, $1,550$18,472 in depreciationresearch and $1,000development, $496,788 in accountingdirector fees and auditexpenses and $127,419 in consulting fees. Our operating

If we are able to obtain financing, we expect that our operational expenses will increase significantly for the six monthsbalance of the fiscal year ended March 31, 2015 consisted2024 and beyond. This would be the result of $5,190increased research and development expenses associated with our product candidates, the development of those candidates in legal feescompliance with regulatory processes, laws and $2,250 in accountingregulations, increased payroll as we take on more help, as well as the expenses associated with our reporting obligations with the Securities and audit fees.Exchange Commission.

We incurredhad other expenses of $4,625$138,163 for the three months ended March 31, 2016, which consistedJune 30, 2023, as a result of interest expense,the loss on the conversion of a note, as compared towith $0 in other expenses of $4,000, also which consisted of interest expense for the three monthssame period ended March 31, 2015. We incurred other income of $1,404 for the six months ended March 31, 2016, which consisted of forgiveness of debt of $10,173, offset by $8,769 in interest expense, as compared to other expenses of $7,725, all of which in the form of interest expense for the three months ended March 31, 2015.

During the six months ended March 31, 2016, we negotiated a settlement of certain legal expenses, in which $10,173 of accrued invoices was forgiven. We do not expect to achieve other income in future quarters.June 30, 2022.

We recorded a net loss of $10,634$718,833 for the three months ended March 31, 2016,June 30, 2023, as compared with a net loss of $6,611$812,689 for the three monthssame period ended March 31, 2015. We recorded2022.

As a net loss of $9,459relatively recently formed pharmaceutical company, the company has limited operations to date, and expects to have reoccurring losses, as is typical with companies in the pharmaceutical industry, for the six months ended March 31, 2016, as compared with a net loss of $15,195 forforeseeable future. As explained above, the six months ended March 31, 2015.company intends to raise capital and ramp up its efforts to bring its product candidates to market. This will require significant capital, product development to continue and complete and momentum on those product candidates through the regulatory process. There are no assurances that we will be able to generate revenues and achieve profitable operations.

Liquidity and Capital Resources

As of March 31, 2016,June 30, 2023, we had $2,818$231,207 in current assets, consisting mostly of a deferred tax credit, and currentlycurrent liabilities of $257,879.$2,310,167. We had a working capital deficit of $257,061$2,078,960 as of June 30, 2023, compared with a working capital deficit of $1,889,920as of March 31, 2016.2023.

Operating activitiesWe used $24,813 in cash for operating activities of $75,467 for the sixthree months ended March 31, 2016,June 30, 2023, as compared with $10,844 in cash used of $216,121 for the same period ended March 31, 2015.2022. Our negative operating cash flow for the six months ended March 31, 20162023 and 2022 periods was mainly attributable tothe result of a decrease in accrued expensesnet loss offset by shares issued for services and asset acquisitions and net loss for the period, offset by an increasechanges in accrued interest. In comparison, our negative operating cash flowassets and liabilities.

Cash used in investing activities was $18,900 for the three months ended March 31, 2015 was mainly attributableJune 30, 2023 as compared to funding the losszero for the period and a decrease in accrued expenses, offset by anthree months ended June 30, 2022. The increase in accrued interest.cash used in investing was related to the acquisition of patent production rights from Alinova Biosciences, Ltd.

Financing activities provided $25,000$68,449 for the sixthree months ended March 31, 2016 when on December 10, 2015, we entered into a $25,000 Demand Promissory Note with an outside investor. Under the terms of the note, simple interest at 10% and all principal are due on demand. In comparison, financing activities provided $20,000 for the same period ended March 31, 2015June 30, 2023, as a result of related party notes offset by treasury shares acquired during the period. Financing activities provided $51,380 for the three months ended June 30, 2022, as a $20,000 Demand Promissory Noteresult of related party notes and cash received for stock issued.

As part of the SPA, executed on October 03, 2022, the shareholder affiliates, through their respective companies, have committed to enter into loan agreements with an outside investor. Underour company to provide up to $4,000,000 USD of working capital, subject to the terms and conditions of the note, simple interest at 10% and all principal are due on demand.SPA dated October 2022 being fulfilled.

Based upon our current financial condition, we do not have sufficient cash to operate our business at the current level for the next twelve12 months. We intend to fund operations through increased sales andshort-term or long-term debt and/or equity financing arrangements, whichhowever this may be insufficient to fund expenditures or other cash requirements. WeDepending upon the outcome of our ongoing discussions with Bright Green, we may have sufficient cash if acquired. Without it, we plan to seek additional financing in a private equity offering to secure funding for operations. There can be no assurance that we will be successful in raising additional funding. If we are not able to secure additional funding, the implementation of our business plan will be impaired. There can be no assurance that such additional financing will be available to us on acceptable terms or at all.

Off Balance Sheet Arrangements

As of March 31, 2016, there wereJune 30, 2023, we had no off balanceoff-balance sheet arrangements.

Going Concern

Our financial statements have beenwere prepared assuming that we will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. We have negative working capital of $2,102,860as of June 30, 2023, and have incurred cumulative losses since inception of $498,758 for the period July 21, 2008 (inception date) through March 31, 2016,$10,295,080. We expect to incur further losses in the development of our business and have been dependent on funding operations through the issuance of convertible debt and private sale of equity securities.from inception. These conditions raise substantial doubt about our ability to continue as a going concern. Management’s plans include continuing to finance operations through the private or public placement of debt and/or equity securities and the reduction of expenditures. At present, the Company remains in discussions with Bright Green Corporation with regard to a potential acquisition of Alterola (as per the previously signed LOI dated August 25, 2022 and SPA dated October, 03 2022)..However, no assurance can be given at this time as to whether we will be able to achieve these objectives. The financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.

Item 3.     Quantitative and Qualitative Disclosures About Market Risk

A smaller reporting company is not required to provide the information required by this Item.

Item 4.     Controls and Procedures

Disclosure Controls and Procedures

We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of March 31, 2016.June 30, 2023. This evaluation was carried out under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of March 31, 2016,June 30, 2023, our disclosure controls and procedures were not effective due to the presence of material weaknesses in internal control over financial reporting.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis. Management has identified the following material weaknesses which have caused management to conclude that, as of March 31, 2016,June 30, 2023, our disclosure controls and procedures were not effective: (i) inadequate segregation of duties and effective risk assessment; and (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines.

Remediation Plan to Address the Material Weaknesses in Internal Control over Financial Reporting

Our company plans to take steps to enhance and improve the design of our internal controls over financial reporting. During the period covered by this quarterly report on Form 10-Q, we have not been able to remediate the material weaknesses identified above. To remediate such weaknesses, we plan to implement the following changes during our fiscal year ending September 30, 2016:March 31, 2024: (i) appoint additional qualified personnel to address inadequate segregation of duties and ineffective risk management; and (ii) adopt sufficient written policies and procedures for accounting and financial reporting. The remediation efforts set out are largely dependent upon our securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such funds, remediation efforts may be adversely affected in a material manner.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the three months ended March 31, 2016June 30, 2023 that have materially affected, or are reasonable likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II – OTHER INFORMATION

Item 1.     Legal Proceedings

We are not a party to any pending legal proceeding. We are not aware of any pending legal proceeding to which any of our officers, directors, or any beneficial holders of 5% or more of our voting securities are adverse to us or have a material interest adverse to us.

Item 1A:  Risk Factors

A smaller reporting company is not required to providePlease see the information requiredRisk Factors contained in our Annual Report on Form 10-K filed with the SEC on July 10, 2023, which are incorporated herein by this Item.reference.

Item 2.     Unregistered Sales of Equity Securities and Use of Proceeds

None

Item 3.     Defaults upon Senior Securities

None

Item 4.     Mine Safety Disclosures

Not applicable.

Item 5.     Other Information

None

Item 6.      Exhibits

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.